Tandem Diabetes Care, Inc. presented new insights from a survey on Tandem Mobi user satisfaction and wearability at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Florida. The survey revealed that 86 percent of participants were satisfied or very satisfied with Tandem Mobi, regardless of their previous therapy. Users agreed that Tandem Mobi helps improve their quality of life. Tandem Mobi, known as the world’s smallest durable automated insulin delivery (AID) system, was made available in the United States in February 2024.
Jordan Pinsker, MD, the chief medical officer at Tandem Diabetes Care, expressed pride in the results, stating that they demonstrate the company’s commitment to enhancing the lives of individuals with diabetes. The survey indicated that Tandem Mobi not only meets but exceeds user expectations. The company aims to continue innovating to offer the diabetes community more choices and an improved quality of life.
The survey included early users who had previously used multiple daily injections (MDI), other insulin pumps, or were former Tandem pump users. The participants showed high satisfaction with the unique wearability features of Tandem Mobi combined with the Control-IQ algorithm. Tandem Mobi’s small size allows users to wear it almost anywhere, providing greater discretion, comfort, and flexibility. The Control-IQ technology helps predict and prevent highs and lows.
For prior MDI users, 84 percent stated that Tandem Mobi reduced the burden of managing their diabetes, 82 percent found it easy to use, and 77 percent felt it gave them more freedom. Among former pump users, 78 percent reported a reduced burden, 88 percent found it easy to use, and 80 percent felt it provided more freedom.
Insights from an independent study involving Tandem Mobi users were also shared at the ADA conference. The study showed an improvement in time spent in range without an increase in time below range. For younger participants, factors such as form factor, portability, discreteness, and wearability were crucial for satisfaction and ongoing use.
Tandem Mobi offers features that cater to the needs of youth with type 1 diabetes, such as a minimum fill of 30 units to reduce insulin waste, a physical on-pump Quick Bolus button for discreet bolusing, on-body wear with a lightweight adhesive sleeve and 5-inch tubing, and personal iPhone compatibility.
The product theater presentation at ADA was recorded and will be accessible on the ADA website for registered attendees and on the Tandem website. Tandem Diabetes Care continues to focus on developing advanced automated insulin delivery systems to lessen the burden of diabetes management and create new possibilities for patients, caregivers, and healthcare providers.
